Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

about

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

P2860

Q59126145-53A1CACE-CF61-4F11-8669-97C1487F6097

P2860

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

Item

http://www.wikidata.org/entity/Q41925730

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Lack of clinically important P ...... citabine/tenofovir alafenamide

@en

type

Item

label

Lack of clinically important P ...... citabine/tenofovir alafenamide

@en

prefLabel

Lack of clinically important P ...... citabine/tenofovir alafenamide

@en

P1476

Lack of clinically important P ...... citabine/tenofovir alafenamide

@en

P2093

Brian P Kearney

http://www.w3.org/2001/XMLSchema#string

Grace Ma

http://www.w3.org/2001/XMLSchema#string

Huyen Cao

http://www.w3.org/2001/XMLSchema#string

John Flaherty

http://www.w3.org/2001/XMLSchema#string

John Ling

http://www.w3.org/2001/XMLSchema#string

Joseph M Custodio

http://www.w3.org/2001/XMLSchema#string

Susan K Chuck

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.

Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States

Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection.

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.

Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.

HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study.

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

P31

scholarly article

P356

10.1002/PRP2.353

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hoa Chu

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28971607

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

P932

5625157

http://www.w3.org/2001/XMLSchema#string

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

about

P2860

P2860

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921

P932